IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Provides Update on Data Showing Effectiveness of THC in Addressing Underlying Cause of Alzheimer’s

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model. Per the update, the aggregation of Aß protein in the cerebral cortex and hippocampus, which is believed to be a primary cause of Alzheimer’s disease, is decreased by as much as 40 percent when treated with varying concentrations of THC. “As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” Ram Mukunda, CEO of IGC, stated in the news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aß40 and Aß42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.” Based on these findings, IGC intends to position IGC-AD1 as a drug that can be used both as a treatment for Alzheimer’s and as a prophylactic treatment for the prevention of Alzheimer’s. The company intends to commercialize a supplement version of IGC-AD1 to be sold as a medical dispensary product.

To view the full press release, visit http://nnw.fm/qe8Zw

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us